Skip to main content
NCBI home page
BMC Infectious Diseases logoLink to BMC Infectious Diseases
. 2021 Jun 24;21:604. doi: 10.1186/s12879-021-06132-5

Correction to: The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis

Yao Li 1,2,#, Xiaojie Huang 2,#, Hui Chen 3, Yuanyuan Qin 1,2, Jianhua Hou 2, Aixin Li 2, Hao Wu 2, Xiaofeng Yan 4, Yaokai Chen 1,✉
PMCID: PMC8228906  PMID: 34167475

Correction to: BMC Infect Dis 20, 410 (2020)

https://doi.org/10.1186/s12879-020-05126-z

Following publication of the original article [1], the authors identified an error in Fig. 3. The correct figure is given below.

Fig. 3.

Fig. 3

Open in a new tab

Forest plots of incidence of CM among CrAg + persons receiving azole vs. no intervention or placebo. Abbreviations: M-H, Mantel Haenszel; CI, confidence interval. (“Azole inter” means “Azole drug intervention”, “No inter or plac” mean “No intervention or placebo”

The original article [1] has been corrected.

Footnotes

Yao Li and Xiaojie Huang contributed equally to this work.

Reference

  • 1.Li, et al. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis. BMC Infect Dis. 2020;20:410. doi: 10.1186/s12879-020-05126-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Infectious Diseases are provided here courtesy of BMC

RESOURCES